AI Engines For more Details: Perplexity Kagi Labs You
Antiviral Activity: Valacyclovir is a prodrug of acyclovir, which means it gets converted to acyclovir in the body. Acyclovir is an antiviral medication that works by inhibiting the replication of herpes simplex virus. Valacyclovir is more bioavailable than acyclovir, allowing for less frequent dosing.
Treatment of Genital Herpes: Valacyclovir is commonly used for the treatment of genital herpes outbreaks. It can help reduce the severity and duration of symptoms such as genital sores, pain, and itching. Valacyclovir does not cure genital herpes but can help manage symptoms and reduce the risk of transmission to sexual partners.
Suppression Therapy for Genital Herpes: In individuals with frequent or severe genital herpes outbreaks, valacyclovir may be used as suppressive therapy to reduce the frequency and severity of recurrences. Continuous daily therapy can help prevent outbreaks and reduce the risk of transmission to sexual partners.
Treatment of Cold Sores: Valacyclovir is also used for the treatment of cold sores (herpes labialis) caused by herpes simplex virus type 1. It can help speed up the healing process and reduce the severity of symptoms when taken at the first sign of a cold sore outbreak.
Herpes Zoster (Shingles): Valacyclovir may be used in the treatment of herpes zoster (shingles) in immunocompetent adults to reduce the duration and severity of acute pain and rash associated with the condition. Early initiation of treatment is recommended for maximum benefit.
Prevention of Recurrent Herpes Simplex Virus Infections: For individuals with frequent recurrences of genital herpes or cold sores, valacyclovir may be used as a preventive measure to reduce the frequency of outbreaks. This is known as episodic or intermittent therapy.
Safety and Tolerability: Valacyclovir is generally well-tolerated, with most adverse effects being mild and transient. Common side effects may include headache, nausea, abdominal pain, and dizziness. Rare but serious side effects such as allergic reactions and renal impairment may occur, particularly in individuals with pre-existing kidney problems.
Dosing and Administration: The dosing regimen for valacyclovir depends on the indication being treated or prevented. It is usually taken orally with or without food. Dosage adjustments may be necessary in individuals with impaired renal function to prevent accumulation of the drug and reduce the risk of adverse effects.
Pregnancy and Lactation: Valacyclovir may be used with caution during pregnancy and lactation if the potential benefits outweigh the risks. Pregnant or breastfeeding individuals should consult their healthcare provider before using valacyclovir.
Drug Interactions: Valacyclovir may interact with certain medications, including probenecid and drugs that affect renal function. Concurrent use of valacyclovir with nephrotoxic agents or drugs eliminated primarily by renal excretion may increase the risk of kidney-related side effects.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Escherichia | genus | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
| 0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
| 0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
| 0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
| 0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
| 0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
| 0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
| 0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
| 0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
| 0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
| 0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
| 0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
| 0 | 1 | Escherichia coli O111 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O121 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O155 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O177 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O26 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O3 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O5 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O86 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O91 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O103 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O78 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O43 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O119 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O157 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O145 | serogroup | Decreases |
| 0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
| 0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
| 0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
| 0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
| 0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
| 0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
| 0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
| 0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
| 0 | 1 | Escherichia coli H20 | serotype | Decreases |
| 0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
| 0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
| 0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
| 0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
| 0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
| 0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
| 0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
| 0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
| 0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
| 0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
| 0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
| 0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
| 0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
| 0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
| 0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Escherichia coli | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.6 | 0.5 | 0.2 |
| ADHD | 3.1 | 0.6 | 4.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 1.4 | 1 |
| Allergies | 3.7 | 2.4 | 0.54 |
| Allergy to milk products | 1.6 | 1.6 | 0 |
| Alopecia (Hair Loss) | 1.1 | 1.1 | |
| Alzheimer's disease | 4.7 | 4.2 | 0.12 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.9 | 1.1 | 1.64 |
| Ankylosing spondylitis | 3.3 | 0.6 | 4.5 |
| Anorexia Nervosa | 1.3 | 1.7 | -0.31 |
| Antiphospholipid syndrome (APS) | 1 | 1 | |
| Asthma | 4.1 | 1.9 | 1.16 |
| Atherosclerosis | 1.6 | 1.5 | 0.07 |
| Atrial fibrillation | 2.6 | 1.6 | 0.63 |
| Autism | 5.6 | 5.5 | 0.02 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.4 | 1.4 | |
| Bipolar Disorder | 1.5 | 1.1 | 0.36 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 1.4 | 1.4 | |
| Cancer (General) | 0.9 | 1.4 | -0.56 |
| Carcinoma | 4.1 | 2.3 | 0.78 |
| Celiac Disease | 1.9 | 2.4 | -0.26 |
| Cerebral Palsy | 1.4 | 1 | 0.4 |
| Chronic Fatigue Syndrome | 2.8 | 3.5 | -0.25 |
| Chronic Kidney Disease | 3.3 | 1.4 | 1.36 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.7 | 0.18 |
| Chronic Urticaria (Hives) | 1.9 | 0.1 | 18 |
| Coagulation / Micro clot triggering bacteria | 1.8 | 1 | 0.8 |
| Cognitive Function | 2.8 | 1.6 | 0.75 |
| Colorectal Cancer | 6.4 | 2.4 | 1.67 |
| Constipation | 1.4 | 1.1 | 0.27 |
| Coronary artery disease | 1.7 | 1.8 | -0.06 |
| COVID-19 | 5 | 5.1 | -0.02 |
| Crohn's Disease | 5.8 | 3.5 | 0.66 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.1 | 1.4 | -0.27 |
| d-lactic acidosis (one form of brain fog) | 0.5 | 0.5 | |
| deep vein thrombosis | 2.4 | 1.1 | 1.18 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 6.8 | 6.3 | 0.08 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.8 | -0.06 |
| Endometriosis | 3.4 | 1.9 | 0.79 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.9 | 1.5 | 0.93 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.5 | 2.5 | 0 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3 | 0.27 |
| gallstone disease (gsd) | 2.7 | 1.2 | 1.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.3 | 2 |
| Generalized anxiety disorder | 2.4 | 2.1 | 0.14 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 1.1 | 0.64 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 0.4 | 1.25 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 2.7 | 0.9 | 2 |
| Heart Failure | 3 | 1 | 2 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.5 | 0.3 | 4 |
| hypercholesterolemia (High Cholesterol) | 1 | 0.1 | 9 |
| hyperglycemia | 2.2 | 1.2 | 0.83 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 3.5 | 2.4 | 0.46 |
| Hypothyroidism | 0 | 0.7 | 0 |
| Hypoxia | 3.1 | 0.3 | 9.33 |
| IgA nephropathy (IgAN) | 1.3 | 2 | -0.54 |
| Inflammatory Bowel Disease | 4.7 | 4.2 | 0.12 |
| Insomnia | 2.2 | 1.6 | 0.38 |
| Intelligence | 1.3 | 1.3 | |
| Intracranial aneurysms | 1.1 | 0.9 | 0.22 |
| Irritable Bowel Syndrome | 5.2 | 3.4 | 0.53 |
| ischemic stroke | 2.4 | 1.4 | 0.71 |
| Liver Cirrhosis | 5.6 | 4.2 | 0.33 |
| Long COVID | 4.6 | 3.9 | 0.18 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.1 | 0.8 | 0.38 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.2 | 0.6 | 1 |
| ME/CFS with IBS | 0.6 | 1.5 | -1.5 |
| ME/CFS without IBS | 0.5 | 1.4 | -1.8 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.9 | 0.6 | 0.5 |
| Metabolic Syndrome | 5.7 | 4.7 | 0.21 |
| Mood Disorders | 6.2 | 4.9 | 0.27 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 4 | 2.9 | 0.38 |
| Multiple system atrophy (MSA) | 0.1 | 0.4 | -3 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.9 | -1.9 | |
| Neuropathy (all types) | 0.5 | 1.9 | -2.8 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.1 | 1.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 2.3 | 0.87 |
| NonCeliac Gluten Sensitivity | 1.1 | 0.6 | 0.83 |
| Obesity | 7.4 | 5.9 | 0.25 |
| obsessive-compulsive disorder | 2.9 | 2.5 | 0.16 |
| Osteoarthritis | 1.6 | 0.9 | 0.78 |
| Osteoporosis | 1.9 | 1.6 | 0.19 |
| pancreatic cancer | 2 | 0.6 | 2.33 |
| Parkinson's Disease | 5.6 | 4 | 0.4 |
| Polycystic ovary syndrome | 3.8 | 2.1 | 0.81 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.1 | 0.09 |
| Primary sclerosing cholangitis | 2 | 1.2 | 0.67 |
| Psoriasis | 2 | 1.7 | 0.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.5 | 3.5 | 0.29 |
| Rosacea | 0.5 | 1 | -1 |
| Schizophrenia | 4.5 | 2.5 | 0.8 |
| scoliosis | 0.8 | 0.8 | |
| Sjögren syndrome | 2.3 | 2 | 0.15 |
| Sleep Apnea | 1.6 | 1.3 | 0.23 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.1 | 0.1 | 20 |
| Stress / posttraumatic stress disorder | 3.1 | 2.2 | 0.41 |
| Systemic Lupus Erythematosus | 3.1 | 1.3 | 1.38 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.1 | 2.3 | 0.35 |
| Type 2 Diabetes | 6 | 5 | 0.2 |
| Ulcerative colitis | 4.4 | 2.9 | 0.52 |
| Unhealthy Ageing | 2.8 | 1.9 | 0.47 |
| Vitiligo | 1.3 | 1.6 | -0.23 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]